The peptide Epitalon, also called Epithalon, Epithalone or the tetrapeptide AEDG, is a short synthetic peptide made up of four amino acids — alanine, glutamic acid, aspartic acid and glycine (Ala-Glu-Asp-Gly) — developed on the basis of research into the pineal gland-derived peptide preparation Epithalamin. [1]
The terminology associated with Epitalon can be confusing, as several variants of this name appear in scientific publications, whilst the similarly sounding term Epithalamin refers to a different substance. This article focuses specifically on identity, nomenclature, chemical sequence and research history, without repeating the broader discussion regarding telomerase, melatonin, longevity or safety described in the article „Epitalon Peptide: A Complete Evidence-Based Guide”.
What is Epitalon Peptide?
The peptide Epitalon is a synthetic peptide made up of four amino acids, namely a tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG). It was designed based on the amino acid composition of the older pineal peptide preparation Epithalamin, and AEDG was subsequently identified as one of the components of the pineal polypeptide complex. [1,2]
Chemically, Epitalon is much smaller and more precisely defined than the tissue-derived peptide preparations from which its developmental history stems. Its four amino acid residues are alanine (Ala), glutamic acid (Glu), aspartic acid (Asp) and glycine (Gly). The abbreviation AEDG derives directly from the single-letter codes of these amino acids. [1]
In scientific literature, Epitalon is most frequently described as a synthetic peptide bioregulator associated with the research programme initiated by Vladimir Khavinson and colleagues. The history of its research encompasses pineal gland biology, melatonin regulation, telomerase, cellular ageing, gene expression, oxidative stress, and retinal biology. These are research areas that scientists have analysed; they should not be interpreted as established medical applications in humans.
A significant historical milestone occurred in 2017. In a biochemical identification study, Khavinson and colleagues analysed the pineal polypeptide complex using mass spectrometry and high-performance liquid chromatography, and reported the detection of AEDG among the tetrapeptides present within it. [2] This result supported the biological connection between synthetic AEDG and the peptide mixture from which its composition was originally developed.
However, this does not mean that commercially synthesised Epitalon is literally extracted from the pineal gland. The compound studied as Epitalon is usually a strictly defined synthetic tetrapeptide.
What Does the Name Epithalon Mean?
Epithalon is an alternative scientific spelling of the name Epitalon, rather than a different peptide. The term derives from the same research tradition concerning Epithalamin and the pineal gland, whereas newer publications increasingly use the name „Epitalon” or the structural designation AEDG. [1]
Scientific literature does not confirm the existence of a separate pharmacological molecule named „Epithalon” that differs from Epitalon. Both spelling variants appear in various publications and refer to the same tetrapeptide Ala-Glu-Asp-Gly.
Older literature often uses the name Epithalon, particularly in publications by Russian and Eastern European research groups. Newer international publications more frequently use the form Epitalon. A comprehensive 2025 review explicitly lists Epitalon, Epithalon and Epithalone as names for the same peptide. [1]
The history of the spelling should therefore be understood primarily as a matter of scientific nomenclature and transliteration, rather than chemical differences.
The similarity between the names Epithalon and Epithalamin can cause additional confusion. Epithalamin is an older preparation derived from pineal tissue, whereas Epithalon is a short, defined peptide developed as part of research into that preparation. The names are historically linked, but they are not chemically interchangeable.
Are Epitalon and Epithalon the same thing?
Yes. Epitalon and Epithalon are names used for the same AEDG tetrapeptide, Ala-Glu-Asp-Gly, and current scientific data does not justify treating the phrase „Epitalon vs Epithalon” as a comparison of two different active peptide sequences. [1]
This is a basic answer to the popular query „epitalon vs epithalon”.
| Appointment | What does it refer to | Another molecule? |
|---|---|---|
| Epitalon | Ala-Glu-Asp-Gly peptide | Not |
| Epithalon | Alternative spelling of Epitalon | Not |
| Epithalone | Less commonly used spelling variant | Not |
| AEDG | AEDG | Not |
| Epithalamin | Complex peptide preparation derived from the pineal gland | Yes |
The same equivalence is directly visible in the peer-reviewed literature. Publications using the name Epithalon repeatedly identify the molecule as Ala-Glu-Asp-Gly, whereas contemporary reviews use the name Epitalon and explicitly list Epithalon as a synonym. [1,3]
Therefore, based on the presented research, there is no evidence-based „difference between Epitalon and Epithalon” regarding the peptide sequence.
What may differ between experiments is the preparation itself — for example, the form of the peptide salt, purity, formulation, concentration, or synthesis method. These differences should not be confused with a difference in the spelling of the name.
Is Epitalon Also Known as Epithalone or AEDG?
Yes. Epitalon is also referred to as Epithalon and, less commonly, Epithalone, while AEDG is an abbreviation for the sequence of the same four amino acids: alanine (A), glutamic acid (E), aspartic acid (D) and glycine (G). [1]
AEDG is a particularly useful scientific designation because it describes the peptide by its amino acid sequence, rather than relying on a transliterated common name.
Therefore, some scientific publications simply refer to the AEDG peptide without explicitly using the name Epitalon. For example, in studies on human stem cells, AEDG was analysed alongside other short peptides such as AED, KED and KE. In this context, AEDG corresponds to the Ala-Glu-Asp-Gly sequence.
A 2025 review similarly notes that some researchers prefer the structural designation AEDG instead of the usual name Epitalon. [1]
The various names can therefore be ordered as follows:
Epitalon = Epithalon = Epithalone = AEDG = Ala-Glu-Asp-Gly, if the literature refers to the conventional peptide composed of four amino acid residues.
There is one caveat, however. Several older sources contain inconsistent representations of the structure or probable sequence errors. A 2025 review points out one unusual publication presenting alternative peptide bonding involving carboxyl side chains instead of the conventional alpha-peptide arrangement and considers it an exceptional representation that has not been reproduced in the wider literature. [1] It should not be used to redefine the standard identity of Epitalon.
What is the amino acid sequence of Epitalon?
The accepted amino acid sequence of Epitalon is Ala-Glu-Asp-Gly, abbreviated as AEDG: alanine, followed by glutamic acid, aspartic acid and glycine, usually joined by conventional alpha-peptide bonds. [1]
Each element of the sequence has a standard biochemical abbreviation:
Ala = alanine
Glu = glutamic acid
Asp = aspartic acid
Gly = glycine
In single-letter notation, that gives A-E-D-G, which is AEDG.
Many independent experimental publications identify Epitalon or Epithalon using the same sequence. For example, studies on gene expression, retinal biology, ageing, immune function and gastrointestinal physiology describe the peptide as Ala-Glu-Asp-Gly.
Particularly significant from the point of view of identity is the 2017 analytical study. It analysed the pineal polypeptide complex and confirmed the presence of free amino acids, dipeptides, tripeptides, tetrapeptides and pentapeptides, with AEDG specifically detected among the tetrapeptide fraction using selected reaction monitoring. [2]
One inconsistency at the source level should be noted. A small number of older records report the final residue as glutamic acid instead of glycine or show an atypical bonding pattern. However, the majority of the literature presented and a contemporary 2025 review identify conventional Epitalon as Ala-Glu-Asp-Gly rather than Ala-Glu-Asp-Glu. [1]
Is Epitalon a tetrapeptide?
Yes. Epitalon is classified as a tetrapeptide because it contains exactly four amino acid residues — Ala, Glu, Asp and Gly — linked together in a single short peptide chain. [1]
„Peptide” is a general term for molecules built from amino acids joined by peptide bonds. The prefix „tetra-” simply indicates the presence of four residues.
Because of this, Epitalon is significantly smaller than many peptide hormones and protein-derived peptide preparations.
Its small size is also significant for the way Khavinson's research programme described short peptide bioregulators. Early research analysed whether small, strictly defined peptide sequences could reproduce some of the biological effects observed in larger, tissue-derived peptide complexes. In a 2002 review, Khavinson described the design of short peptides related to specific tissues based on the amino acid composition of peptide preparations derived from various organs. [3]
Epitalon was developed as part of this approach as a short sequence particularly associated with the pineal gland and the retina. This historical classification helps to understand why so much early research on Epitalon focused on circadian rhythm biology, retinal degeneration, ageing and neuroendocrine regulation.
However, the term Epitalon as a tetrapeptide describes its chemical size rather than its clinical efficacy. A structure composed of four amino acid residues does not in itself confirm any therapeutic benefits.
How Does Epitalon Differ from Epithalamin?
Epitalon is a defined synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, whereas Epithalamin is a much more complex peptide preparation derived from bovine pineal tissue. Epitalon was designed in the course of research on Epithalamin, but these substances should not be considered chemically identical. [1,3]
This distinction is one of the most important terminological issues in the literature concerning Epitalon.
A 2025 review describes Epithalamin as a bovine pineal polypeptide extract, biological research into which began many years before Epitalon was developed as a defined synthetic peptide. Analysis of the amino acid composition of Epithalamin contributed to the design of AEDG. [1]
Simply put:
| Feature | Epitalon | Epithalamin |
|---|---|---|
| Composition | Defined tetrapeptide | Complex peptide mixture |
| Sequence | Ala-Glu-Asp-Gly | Absence of a single sequence restricted solely to AEDG |
| Type | Synthetic tetrapeptide | Peptide preparation derived from pineal tissue |
| Other names | Epithalon, Epithalone, AEDG | Epithalamin |
| Historical account | Developed based on the analysis of Epithalamin | Legacy source preparation for the research programme |
Some older reviews discuss the biological effects of both substances together because their research histories are closely linked. However, this does not justify automatically transferring all clinical observations concerning Epithalamin to Epitalon.
This distinction becomes particularly important when evaluating claims regarding human research. A clinical experiment utilising Epithalamin cannot automatically be presented as a clinical trial of purified synthetic AEDG unless the preparation used has been unequivocally identified as Epitalon.
The detection of AEDG in the pineal polypeptide complex in 2017 helps to explain this relationship, but it does not mean that Epithalamin and Epitalon are synonyms. [2]
Who developed Epitalon?
Epitalon was developed as part of a short peptide research programme conducted mainly by Russian gerontologist Vladimir Khavinson and his colleagues, following earlier work on Epithalamin and other tissue-derived peptide preparations in St Petersburg research institutions. [1,3]
The story begins with Epithalamin, not Epitalon itself.
According to a 2025 historical review, the term Epithalamin appeared in scientific research in the 1970s, with early research into the pineal peptide preparation being led primarily by Vladimir Khavinson and Vladimir Anisimov. Subsequent work aimed to identify much shorter sequences capable of reproducing selected biological effects of tissue-specific peptide preparations. [1]
Khavinson later described this broader research concept in his 2002 review „Peptides and Ageing”. He explained therein that data on the amino acid composition of peptide preparations derived from tissues were used to design short synthetic peptides associated with various organs. The four-residue sequence Ala-Glu-Asp-Gly, named Epitalon, was associated with the pineal gland and the retina. [3]
In a later analytical study published in 2017, Khavinson, Kopylov, Vaskovsky, Ryzhak and Linkova reported the detection of AEDG in the pineal polypeptide complex, providing experimental support for the link between the synthetic sequence and the original pineal-derived preparation. [2]
It is therefore more precise to state that Khavinson and colleagues developed Epitalon as part of a broader research programme into peptide bioregulators, rather than attributing all aspects of its development to a single discovery.
The historical origin also explains an unusual feature of the literature: a large proportion of early research on Epitalon comes from groups associated with Khavinson. More recent independent studies have broadened the scope of AEDG analysis, but the concentration of authorship in the older literature remains important when assessing the overall strength and independence of the evidence.
Naming and Identity Data Restrictions
The question of Epitalon's identity is considerably more straightforward than the question of whether it induces clinically significant health effects. Contemporary reviews and numerous primary studies consistently identify the conventional compound as Ala-Glu-Asp-Gly (AEDG) and treat Epitalon, Epithalon and Epithalone as names for the same peptide. [1]
However, there are certain inconsistencies in older literature. Some sources contain typographical errors or variant representations of the structure, and one rare representation described in a 2025 review uses non-standard bonding via side chains. [1] Such isolated sources should be noted, but should not be used to suggest that the name Epitalon routinely refers to several different, established molecules.
It is much more important to make a distinction between Epitalon and Epithalamin. Since Epithalamin is a complex preparation derived from the pineal gland, data obtained from its use should not be automatically attributed to purified AEDG.
Finally, precise knowledge of what Epitalon is does not yet tell us how it works clinically. Its chemical identity is well defined, whereas its human efficacy, optimal clinical application, and long-term safety remain considerably less certain.
Disclaimer
This material is for educational and scientific-information purposes only and does not constitute medical advice, a diagnosis, therapeutic guidance, or a recommendation for the use of Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) remains an experimental compound: the FDA lists Epitalon as a recognized substance, but explicitly notes that substance registration does not imply regulatory approval, while the FDA orphan drug database indicates that its earlier designation regarding retinitis pigmentosa did not mean FDA approval for that orphan indication. The EMA medicines database covers centrally authorized medicinal products, and the official EMA search analysed for the purposes of this article did not identify any centrally authorized medicinal product containing Epitalon; products authorized nationally in the EU require separate verification in national registers. Clinical evidence involving humans remains limited compared to the much larger preclinical and mechanistic literature.
References
[1] Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 26(6), 2691. https://doi.org/10.3390/ijms26062691
[2] Khavinson, V. K., Kopylov, A. T., Vaskovsky, B. V., Ryzhak, G. A., & Linkova, N. S. (2017). Identification of peptide AEDG in the polypeptide complex of the pineal gland. Bulletin of Experimental Biology and Medicine, 164(1), 41–43. https://doi.org/10.1007/s10517-017-3922-8
[3] Khavinson, V. K. (2002). Peptides and ageing. Neuro Endocrinology Letters, 23(Suppl. 3), 11–144. https://pubmed.ncbi.nlm.nih.gov/12374906/